Literature DB >> 28484878

The association between creatinine versus cystatin C-based eGFR and cardiovascular risk in children with chronic kidney disease using a modified PDAY risk score.

Sheena Sharma1, Michelle R Denburg2,3, Susan L Furth2,3.   

Abstract

BACKGROUND: Children with chronic kidney disease (CKD) have a high prevalence of cardiovascular disease (CVD) risk factors which may contribute to the development of cardiovascular events in adulthood. Among adults with CKD, cystatin C-based estimates of glomerular filtration rate (eGFR) demonstrate a stronger predictive value for cardiovascular events than creatinine-based eGFR. The PDAY (Pathobiological Determinants of Atherosclerosis in Youth) risk score is a validated tool used to estimate the probability of advanced coronary atherosclerotic lesions in young adults.
OBJECTIVE: To assess the association between cystatin C-based versus creatinine-based eGFR (eGFR cystatin C and eGFR creatinine, respectively) and cardiovascular risk using a modified PDAY risk score as a proxy for CVD in children and young adults.
METHODS: We performed a cross-sectional study of 71 participants with CKD [median age 15.5 years; inter-quartile range (IQR) 13, 17], and 33 healthy controls (median age 15.1 years; IQR 13, 17). eGFR was calculated using age-appropriate creatinine- and cystatin C-based formulas. Median eGFR creatinine and eGFR cystatin C for CKD participants were 50 (IQR 30, 75) and 53 (32, 74) mL/min/1.73 m2, respectively. For the healthy controls, median eGFR creatinine and eGFR cystatin were 112 (IQR 85, 128) and 106 mL/min/1.73m2 (95, 123) mL/min/1.73 m2, respectively. A modified PDAY risk score was calculated based on sex, age, serum lipoprotein concentrations, obesity, smoking status, hypertension, and hyperglycemia.
RESULTS: Modified PDAY scores ranged from -2 to 20. The Spearman's correlations of eGFR creatinine and eGFR cystatin C with coronary artery PDAY scores were -0.23 (p = 0.02) and -0.28 (p = 0.004), respectively. Ordinal logistic regression also showed a similar association of higher eGFR creatinine and higher eGFR cystatin C with lower PDAY scores. When stratified by age <18 or ≥18 years, the correlations of eGFR creatinine and eGFR cystatin C with PDAY score were modest and similar in children [-0.29 (p = 0.008) vs. -0.32 (p = 0.004), respectively]. Despite a smaller sample size, the correlation in adults was stronger for eGFR cystatin C (-0.57; p = 0.006) than for eGFR creatinine (-0.40; p = 0.07).
CONCLUSIONS: Overall, the correlation between cystatin C- or creatinine-based eGFR with PDAY risk score was similar in children. Further studies in children with CKD should explore the association between cystatin C and cardiovascular risk.

Entities:  

Keywords:  Cardiovascular disease; Cardiovascular risk; Chronic kidney disease; PDAY; Pathobiological Determinants of Atherosclerosis in Youth

Mesh:

Substances:

Year:  2017        PMID: 28484878     DOI: 10.1007/s00467-017-3683-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  16 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Estimated kidney function based on serum cystatin C and risk of subsequent coronary artery calcium in young and middle-aged adults with preserved kidney function: results from the CARDIA study.

Authors:  Nisha Bansal; Eric Vittinghoff; Carmen A Peralta; Michael G Shlipak; Vanessa Grubbs; David R Jacobs; David Siscovick; Michael Steffes; John Jeffrey Carr; Kirsten Bibbins-Domingo
Journal:  Am J Epidemiol       Date:  2013-06-27       Impact factor: 4.897

Review 3.  Cystatin C: an emerging biomarker in cardiovascular disease.

Authors:  Christos Angelidis; Spyridon Deftereos; Georgios Giannopoulos; Nikolaos Anatoliotakis; Georgios Bouras; Georgios Hatzis; Vasiliki Panagopoulou; Vlasios Pyrgakis; Michael W Cleman
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

4.  Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease.

Authors:  Amy C Wilson; Michael F Schneider; Christopher Cox; Larry A Greenbaum; Jeffrey Saland; Colin T White; Susan Furth; Bradley A Warady; Mark M Mitsnefes
Journal:  Clin J Am Soc Nephrol       Date:  2011-10-06       Impact factor: 8.237

5.  Elevated serum cystatin C is an independent predictor of cardiovascular events in people with relatively normal renal function.

Authors:  Lei Meng; Ying Yang; Li-Tong Qi; Xue-jing Wang; Guo-Bin Xu; Bao-Wei Zhang
Journal:  J Nephrol       Date:  2012 May-Jun       Impact factor: 3.902

6.  Cystatin C, cardiometabolic risk, and body composition in severely obese children.

Authors:  Pilar Codoñer-Franch; Esther Ballester-Asensio; Lorena Martínez-Pons; Jorge Vallecillo-Hernández; Almudena Navarro-Ruíz; Ramón del Valle-Pérez
Journal:  Pediatr Nephrol       Date:  2010-11-19       Impact factor: 3.714

7.  Risk scores predict atherosclerotic lesions in young people.

Authors:  C Alex McMahan; Samuel S Gidding; Zahi A Fayad; Arthur W Zieske; Gray T Malcom; Richard E Tracy; Jack P Strong; Henry C McGill
Journal:  Arch Intern Med       Date:  2005-04-25

8.  Cystatin C identifies cardiovascular risk better than creatinine-based estimates of glomerular filtration in middle-aged individuals without a history of cardiovascular disease.

Authors:  P Svensson-Färbom; M Ohlson Andersson; P Almgren; B Hedblad; G Engström; M Persson; A Christensson; O Melander
Journal:  J Intern Med       Date:  2013-12-20       Impact factor: 8.989

9.  Design and methods of the NiCK study: neurocognitive assessment and magnetic resonance imaging analysis of children and young adults with chronic kidney disease.

Authors:  Erum A Hartung; Nina Laney; Ji Young Kim; Rebecca L Ruebner; John A Detre; Hua-Shan Liu; Christos Davatzikos; Guray Erus; Jimit J Doshi; Robert T Schultz; John D Herrington; Abbas F Jawad; Divya G Moodalbail; Ruben C Gur; Allison M Port; Jerilynn Radcliffe; Stephen R Hooper; Susan L Furth
Journal:  BMC Nephrol       Date:  2015-04-30       Impact factor: 2.388

10.  Clinical utility of serum cystatin C in predicting coronary artery disease in patients without chronic kidney disease.

Authors:  Azza Dandana; Imen Gammoudi; Abdelkader Chalghoum; Hinda Chahed; Faouzi Addad; Salima Ferchichi; Abdelhedi Miled
Journal:  J Clin Lab Anal       Date:  2014-01-29       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.